GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannara Biotech Inc (OTCPK:LOVFF) » Definitions » Book Value per Share

LOVFF (Cannara Biotech) Book Value per Share : $0.72 (As of Feb. 2025)


View and export this data going back to 2019. Start your Free Trial

What is Cannara Biotech Book Value per Share?

Cannara Biotech's book value per share for the quarter that ended in Feb. 2025 was $0.72.

During the past 12 months, Cannara Biotech's average Book Value Per Share Growth Rate was 16.90% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 10.10% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 10.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Cannara Biotech was 51.10% per year. The lowest was 4.50% per year. And the median was 14.70% per year.

Cannara Biotech's current price is $1.0054. Its book value per share for the quarter that ended in Feb. 2025 was $0.72. Hence, today's PB Ratio of Cannara Biotech is 1.40.

During the past 7 years, the highest P/B Ratio of Cannara Biotech was 3.66. The lowest was 0.62. And the median was 1.51.

Warning Sign:

Cannara Biotech Inc stock PB Ratio (=1.34) is close to 2-year high of 1.41.


Cannara Biotech Book Value per Share Historical Data

The historical data trend for Cannara Biotech's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cannara Biotech Book Value per Share Chart

Cannara Biotech Annual Data
Trend Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
Book Value per Share
Get a 7-Day Free Trial 0.39 0.58 0.59 0.66 0.72

Cannara Biotech Quarterly Data
May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.65 0.67 0.72 0.72 0.72

Competitive Comparison of Cannara Biotech's Book Value per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Cannara Biotech's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cannara Biotech's PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cannara Biotech's PB Ratio distribution charts can be found below:

* The bar in red indicates where Cannara Biotech's PB Ratio falls into.


;
;

Cannara Biotech Book Value per Share Calculation

Cannara Biotech's Book Value Per Share for the fiscal year that ended in Aug. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(64.41-0.00)/90.02
=0.72

Cannara Biotech's Book Value Per Share for the quarter that ended in Feb. 2025 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(65.87-0.00)/91.43
=0.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Cannara Biotech  (OTCPK:LOVFF) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Cannara Biotech Book Value per Share Related Terms

Thank you for viewing the detailed overview of Cannara Biotech's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Cannara Biotech Business Description

Traded in Other Exchanges
Address
1055 West Georgia Street, Suite 2050, Vancouver, BC, CAN, V6E 3P3
Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .